Abacus Medicine Pharma Services (AMPS) is the pharmaceutical services division of the Abacus Medicine Group.
The purpose statement of the Abacus Medicine Group is Better Access · Better Healthcare.
The company was founded in 2004 by CEO Flemming Wagner and his father John Wagner ( 1932 – 2018 ) to improve access to original prescription medicines throughout Europe, driven by the vision of providing better access to medicines which supports better healthcare for patients.
The Group has enjoyed rapid growth and now employs over 1,200 people across 9 locations, has over 8,000 MAs and distributes over 22M units/year.
Abacus Medicine Pharma Services has built a leadership and management team with vast experience across the pharma and pharma services sectors. This combination of people experience with the market-leading sourcing and analytical capabilities of Abacus Medicine has created a new pharma services company designed to support the existing and future pharma and biotechnology industries.
AMPS provides the market with four services offering support to our clients across the entire pharmaceutical product life cycle.
Starting with Clinical Trial Solutions, we provide tailored comparator sourcing solutions to support the efficient running of clinical trials for biosimilar, biotechnology and innovative pharmaceutical companies. From pre-clinical to phase I, II and III, via our parent company we have continual access to over 8,000 key brands across multiple markets, and sophisticated market analysis tools which gives us an unrivalled inventory and supplier network. These unique capabilities allow us to provide a wide range of innovative hybrid sourcing solutions for our client partners.
The Commercial Partnerships service focuses on supporting pharma companies and provides an integrated end-to-end approach to bringing licensed products to European markets. We are capable of developing market access solutions that provide patients the fastest access to new treatments as well as implementing high-impact commercial strategies that capture critical value creation opportunities. Furthermore, we provide a high touch, specialty distribution service for the pharmaceutical products, delivering directly to healthcare establishments in a timely and compliant manner. Finally, we are capable of providing ancillary services such as labelling and packaging.
Our breadth of knowledge and experience across the pharmaceutical industry and all of the capabilities of Abacus Medicine Pharma Services allow for the identification and implementation of innovative and bespoke solutions that support our partners, physicians and patients' unmet needs. We have a special expertise in products that are intended for the treatment of rare and orphan diseases.
A service that supports products and companies that are in the late stages of development is our Managed Access Program (MAP) service. Abacus Medicine Pharma Services is a strategic partner to the pharmaceutical and biotech industry. MAPs provide a framework for a partnership where we create, implement and manage a programme on behalf of a drug manufacturer to provide access to their drug in countries where it is not commercially available. This can be either in the prelaunch or the post launch stage of the product lifecycle. Each program is designed to meet the specific needs of the manufacturer.
Finally our Unlicensed Medicines service helps healthcare professionals and patients gain access to products that are not licensed locally but are licensed in other markets. Patients with an unmet medical need often require access to a medicine that is not commercially available in the country where they live. When we receive such a request from a healthcare professional, if we do not already have it in stock, we find a source of the medicine and ensure we deliver it, in compliance with appropriate regulations, to the relevant medical establishment ready for the patient to receive treatment.
We are a versatile and fast-reacting pharma services company, ideally positioned to support the biotech, biosimilar and pharma companies that are driving pharmaceutical innovation.
